Rituximab shows no effect on remission in patients with refractory nephrotic syndrome: A MOOSE-compliant meta-analysis

To assess the efficacy of rituximab in treatment of refractory nephrotic syndrome (NS) compared with other agents. Studies were searched from Web of Science, PubMed, and CNKI up to April 2016. The standardized mean difference or relative risk or odds ratio and 95% confidence intervals were used to a...

Descripción completa

Detalles Bibliográficos
Autores principales: Yin, Supei, He, Ting, Li, Yi, Wang, Jingshuang, Zeng, Wei, Tang, Sha, Zhao, Jinghong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2016
Materias:
5200
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5268020/
https://www.ncbi.nlm.nih.gov/pubmed/27977574
http://dx.doi.org/10.1097/MD.0000000000005320

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5268020/
https://www.ncbi.nlm.nih.gov/pubmed/27977574
http://dx.doi.org/10.1097/MD.0000000000005320

Ejemplares similares